State Street reports 4.6% stake in Travere Therapeutics
State Street Corporation reported its beneficial ownership of Travere Therapeutics, Inc. common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
State Street Corporation reported its beneficial ownership of Travere Therapeutics, Inc. common stock. State Street, through its investment management subsidiaries, reported beneficially owning 4,256,224 shares of common stock, representing 4.6% of the class as of June 30, 2026.
The shares are held with no sole voting or dispositive power; State Street reported shared voting power over 4,010,969 shares and shared dispositive power over 4,256,224 shares. The filing indicates ownership of 5 percent or less of the class and identifies several State Street Global Advisors entities as the investment adviser subsidiaries through which the holdings are maintained.
Key Figures
Key Terms
beneficially owned financial
parent holding company financial
beneficiaries of employee benefit plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Travere Therapeutics (TVTX) does State Street Corporation report owning?
Does State Street’s Travere Therapeutics (TVTX) stake exceed 5 percent of the class?
Which State Street subsidiaries are associated with the Travere Therapeutics (TVTX) holdings?
Who signed the Travere Therapeutics (TVTX) ownership report for State Street?
AI-generated analysis. How Rhea-AI works. Not financial advice.